TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07919210: A Phase 1, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety, Reactogenicity, and Immunogenicity of a Preventative Vaccine for Marburg Virus (mRNA-1519) in Healthy Adult Participants 18 to

Sponsor: ModernaTX, Inc. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 64 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT07919210 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07919210 Rescue Dossier →